4.5 Article

International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes

期刊

EUROPEAN JOURNAL OF HEART FAILURE
卷 12, 期 11, 页码 1253-1260

出版社

WILEY
DOI: 10.1093/eurjhf/hfq133

关键词

Heart failure; Emergency; Geographical differences

资金

  1. National Heart, Lung and Blood Institute [K23HL085387]
  2. PDL BioPharma
  3. Biosignetics
  4. Inovise Medical Inc.
  5. Abbott Point-of-Care
  6. NIH/NHLBI
  7. Corthera
  8. BRAHMS
  9. Merck
  10. Abbott Diagnostics
  11. Meso Scale Discovery
  12. NIH / NHLBI, Centers for Disease Control [R01HL088459-02]
  13. Biosite
  14. Siemens
  15. Nanosphere
  16. sanofi-Aventis
  17. BMS
  18. Molecular Insights
  19. Johnson & Johnson/Scios, Inc.
  20. GlaxoSmithKline
  21. Schering-plough
  22. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership
  23. Bmeye
  24. Mitsubishi
  25. Abbott
  26. Beckman-coulter
  27. Heartscape
  28. EKR
  29. Medicines Co
  30. Guidant
  31. Inverness and Edwards Life Sciences

向作者/读者索取更多资源

Results from investigations in one area of the world may not translate to another if patient characteristics and practices differ. We examine differences in the presentation and management of emergency department (ED) patients with dyspnoea from acute heart failure syndromes (AHFS) between the USA, Western Europe, and Eastern Europe. The URGENT Dyspnoea study was a multinational prospective observational study of dyspnoeic ED patients with AHFS from 18 countries. Acute heart failure syndrome patients from the USA and Western and Eastern Europe underwent dyspnoea assessments within 1 h of the first physician evaluation. Patient characteristics, evaluation, and treatments were compared between geographical regions using analysis of variance and chi(2) tests. Four hundred and ninety-three patients with AHFS met the inclusion criteria. Participants in the USA were more frequently non-white, younger, on chronic beta-blocker therapy, and with an ejection fraction < 40% when compared with Eastern and Western Europe. Patients from Eastern Europe were more likely to present with de novo heart failure and have ischaemic electrocardiogram changes. Pulmonary oedema was more common on chest radiograph in Western Europe, but natriuretic peptide levels were elevated in all three regions. Diuretic use was similar across all the regions. Intravenous nitroglycerin was used more frequently in Eastern (32.8%) and Western Europe (24.4%) compared with the USA (2.5%). International differences in AHFS presentations and management between regions suggest results from clinical trials in one region may not translate directly to another. These differences should be considered when designing trials and interpreting the results from clinical investigations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据